The global Pet Cancer Therapeutics Market is witnessing substantial growth as pet owners increasingly prioritize advanced healthcare solutions for companion animals. The rising prevalence of cancer among pets, growing awareness regarding veterinary oncology, and advancements in treatment modalities such as immunotherapy, targeted therapy, and chemotherapy are creating significant opportunities...

According to a new report from Intel Market Research, the global Crizotinib Drugs market was valued at USD 582.4 million in 2025 and is projected to reach USD 1,043.7 million by 2034, growing at a CAGR of 6.7% during the forecast period (2026–2034). This growth is propelled by the rising global incidence of lung cancer, increasing adoption of molecular diagnostic testing for genetic...

The global Epidermal Growth Factor Receptor (EGFR) inhibitor industry is witnessing substantial momentum due to the increasing prevalence of cancer, growing adoption of targeted therapies, and advancements in precision medicine. The Epidermal Growth Factor Receptor Inhibitor Market size is expected to reach US$ 32.14 Billion by 2034 from US$ 15.92 Billion in 2025. The market is estimated to...

According to a new report from Intel Market Research, the global Cabozantinib Drug market was valued at USD 2.12 billion in 2025 and is projected to reach USD 4.01 billion by 2034, growing at a robust CAGR of 7.5% during the forecast period (2026–2034). This growth is propelled by the escalating global burden of cancer, particularly renal and liver cancers, alongside expanding clinical...

According to a new report from Intel Market Research, the global TKIs for Breast Cancer market was valued at USD 1.82 billion in 2025 and is projected to reach USD 3.74 billion by 2034, growing at a CAGR of 7.3% during the forecast period (2025–2034). This growth is propelled by the rising global incidence of breast cancer, growing adoption of precision oncology, and increasing regulatory...

The United States Antibody‑Drug Conjugate (ADC) for Solid Tumors market size was valued at approximately USD 0.55 billion in 2025. The market is projected to grow from approximately USD 0.58 billion in 2026 to around USD 1.04 billion by 2034, exhibiting a CAGR of about 8.9% during the forecast period. Antibody‑Drug Conjugates are targeted therapeutics that combine a monoclonal antibody that...